Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts

Lown, 2013, Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision, Bone Marrow Transplant, 48, 210, 10.1038/bmt.2012.54 Scaradavou, 2013, Double-unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia, Blood, 121, 752, 10.1182/blood-2012-08-449108 Aversa, 2008, Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States, Bone Marrow Transplant, 41, 473, 10.1038/sj.bmt.1705966 O'Reilly, 1987, HLA nonidentical T cell–depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease, Transplant Proc, 19, 55 Federmann, 2012, Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study, Haematologica, 97, 1523, 10.3324/haematol.2011.059378 Ruggeri, 2010, Alternative donor hematopoietic stem cells transplantation for adults with acute myeloid leukemia: umbilical cord blood or haploidentical donors?, Best Pract Res Clin Haematol, 23, 207, 10.1016/j.beha.2010.06.002 Ciceri, 2008, A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation, Blood, 112, 3574, 10.1182/blood-2008-02-140095 Lu, 2006, Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, Blood, 107, 3065, 10.1182/blood-2005-05-2146 Luznik, 2008, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 14, 641, 10.1016/j.bbmt.2008.03.005 Raiola, 2013, Unmanipulated haploidentical bone marrow transplant and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning, Biol Blood Marrow Transplant, 19, 117, 10.1016/j.bbmt.2012.08.014 Burroughs, 2008, Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma, Biol Blood Marrow Transplant, 14, 1279, 10.1016/j.bbmt.2008.08.014 Raiola, 2014, Unmanipulated haploidentical bone marrow transplantation following nonmyeloablative conditioning and post-transplantation cyclophosphamide for advanced Hodgkin's lymphoma, Bone Marrow Transplant, 49, 190, 10.1038/bmt.2013.166 Gratwohl, 2012, The EBMT risk score, Bone Marrow Transplant, 47, 749, 10.1038/bmt.2011.110 Sanz, 2012, Single-unit umbilical cord blood transplantation from unrelated donors in patients with haematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen, Bone Marrow Transplant, 47, 1287, 10.1038/bmt.2012.13 Di Bartolomeo, 2013, Haploidentical, unmanipulated, G-CSF–primed bone marrow transplantation for patients with high-risk hematologic malignancies, Blood, 121, 849, 10.1182/blood-2012-08-453399 Rambaldi, 2012, Outcome of patients activating an unrelated donor search: the impact of transplant with reduced-intensity conditioning in a large cohort of consecutive high-risk patients, Leukemia, 26, 1779, 10.1038/leu.2012.55 Frassoni, 2008, Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study, Lancet Oncol, 9, 831, 10.1016/S1470-2045(08)70180-3 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Passweg, 2013, Hematopoietic SCT in Europe: data and trends in 2011, Bone Marrow Transplant, 48, 1161, 10.1038/bmt.2013.51 Noviello, 2012, Early reconstitution of T-cell immunity to CMV after HLA-haploidentical hematopoietic stem cell transplantation is a strong surrogate biomarker for lower non-relapse mortality rates, ASH Annual Meeting Abstracts, 120, 4191 Bashey, 2013, T-cell–replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation, J Clin Oncol, 31, 1310, 10.1200/JCO.2012.44.3523 Reisner, 2011, Haploidentical hematopoietic transplantation: current status and future perspectives, Blood, 118, 6006, 10.1182/blood-2011-07-338822 Brunstein, 2011, Alternative donor transplantation after reduced-intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts, Blood, 118, 282, 10.1182/blood-2011-03-344853 Armand, 2012, A disease risk index for patients undergoing allogeneic stem cell transplantation, Blood, 120, 905, 10.1182/blood-2012-03-418202 Rocha, 2013, Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies, Transplantation, 95, 1284, 10.1097/TP.0b013e318288ca4d